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Abstract
Precise fluorescence-guided surgery (FGS) for pancreatic cancer has the potential to greatly 
improve the outcome in this recalcitrant disease. In order to achieve this goal, we have used 
genetic reporters to color code cancer and stroma cells in a patient-derived orthotopic xenograft 
(PDOX) model. The telomerase-dependent green fluorescent protein (GFP) containing adenovirus 
OBP401 was used to label the cancer cells of the pancreatic cancer PDOX. The PDOX was 
previously grown in a red fluorescent protein (RFP) transgenic mouse that stably labeled the 
PDOX stroma cells bright red. The color-coded PDOX model enabled FGS to completely resect 
the pancreatic tumors including stroma. Dual-colored FGS significantly prevented local 
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recurrence, which bright-light surgery (BLS) or single color could not. FGS, with color-coded 
cancer and stroma cells has important potential for improving the outcome of recalcitrant cancer.
Keywords
fluorescence-guided surgery (FGS); patient-derived orthotopic xenograft (PDOX); adenovirus 
OBP-401; green fluorescent protein; GFP; red fluorescent protein; RFP; pancreatic cancer; stroma; 
color-coded fluorescence imaging
Introduction
Accurate visualization of primary tumor margins and metastatic deposits at the time of 
surgery is critical to determine the success of a cancer operation. In order to achieve this 
goal, there is currently intense interest in labeling of tumors for fluorescence-guided surgery 
(FGS). In the clinic, sentinel lymph nodes were labeled by the near-infrared (NIR) 
fluorescing dye indocyanine.1 However, indocyanine does not specifically label tumor cells. 
5-Aminolevulinic acid, a precursor of hemoglobin, can selectively label malignant glioma. 
Porphyrin fluorescence in the brain tumor can then be visualized with a fluorescence 
neurosurgical microscope.2 FGS resulted in a higher 6-month progression-free survival rates 
than did those who had bright-light surgery (BLS).2 Folate conjugated to fluorescein 
isothiocyanate (FITC) targeted the folate receptor-α (FR-α), which is often overexpressed in 
ovarian cancers. FGS, with a real-time multispectral intraoperative fluorescence imaging 
system, enabled tumors less than 1 mm in diameter to be resected. However, FR-α may not 
generally overexpressed in cancer.3
In other studies, monoclonal antibodies against cancer antigen 19-9 (CA19-9) or carcino-
embryonic antigen (CEA), were conjugated to a green fluorophore and delivered 
intravenously into nude mice with orthotopic human pancreatic or colon tumors.4 The 
fluorescent antibodies adhered to the CEA or CA19-9 antigens of CEA- or CA19-9–
expressing cancer cells, respectively, making the tumors become fluorescent and visible and 
resectable under fluorescence guidance,4 which in subsequent studies resulted in reduced 
recurrence and increased survival compared to BLS.3,5-12
Kishimoto et al.13 selectively labeled tumors with green fluorescent protein (GFP) using a 
telomerase-dependent adenovirus (OBP-401) that expresses the gfp gene only in cancer 
cells. The labeled tumors could then be resected under fluorescence guidance. OBP-401 
GFP-labeled tumors that recurred after fluorescence-guided surgery maintained GFP 
expression.14 Thus, imaging cancer recurrence and metastasis is also possible with OBP-401 
GFP labeling, which is not possible with non-genetic probes such as fluorescent antibodies.3
OBP-401 could selectively label soft-tissue sarcoma (STS) with GFP in an orthotopic nude-
mouse model. OBP-401-based FGS resulted in superior resection of STS compared to BLS. 
OBP-401 based-FGS improved disease free survival as well as preserved muscle function 
compared with BLS.15
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Glioblastoma multiforme (GBM) is one of the most invasive of cancers and is not totally 
resectable using standard BLS or current FGS. OBP-401 infection brightly and selectively 
labeled GBM with GFP for effective FGS in orthotopic nude-mouse models without 
recurrence.16
It is also possible to selectively label the stroma of a tumor. Pancreatic-cancer patient-
derived orthotopic xenografts (PDOX) tumors were passaged orthotopically in transgenic 
nude mice ubiquitously expressing red fluorescent protein (RFP). The primary patient 
tumors acquired RFP-expressing stroma. The RFP-expressing stroma included cancer-
associated fibroblasts (CAFs) and tumor-associated macrophages (TAMs). The RFP stroma 
persisted in the tumors after passage.17 It was possible to image the brightly fluorescent 
tumors noninvasively longitudinally as they progressed after passage to nontransgenic nude 
mice.18
In the present study, we demonstrate a novel approach to FGS, with cancer cells labeled 
with GFP by GFP-401 and stroma labeled with red fluorescence protein (RFP) by previous 
growth in RFP transgenic mice. Dual-color FGS was more effective than BLS or single-
color FGS to prevent recurrence in a pancreatic cancer patient-derived orthotopic xenograft 
(PDOX) nude-mouse model.
Materials and Methods
GFP-expressing telomerase-specific adenovirus
Adenovirus OBP-401 contains a promoter element of the human telomerase reverse 
transcriptase (hTERT) gene which drives the expression of E1A and E1B genes linked to an 
internal ribosome entry site. OBP-401 also contains the GFP gene which is driven by the 
CMV promoter. The virus only replicates in cancer cells, labeling them with the GFP 
gene.13
Mice
Athymic nude nu/nu mice or transgenic RFP nu/nu mice 19 (AntiCancer, Inc., San Diego, 
CA, USA) (5 weeks old), were kept in a barrier facility under HEPA filtration. Mice were 
fed with autoclaved laboratory rodent diet (Tecklad LM-485, Western Research Products). 
All animal studies were conducted in accordance with the principals and procedures outlined 
in the National Institutes of Health Guide for the Care and Use of Laboratory Animals under 
Assurance no. A3873-01.
Establishment of patient pancreatic cancer
Pancreatic cancer tumor tissue from a single patient was originally obtained at surgery at the 
MD Anderson Cancer Center and cut into 3-mm3 fragments and transplanted 
subcutaneously in NOD/SCID mice.20,21
Patient-derived orthotopic xenograft (PDOX®)
The fluorescent PDOX (fPDOX) model was passaged, using surgical orthotopic 
implantation (SOI) 22 of tumor previously grown in the NOD/SCID mice, in transgenic RFP 
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nude mice.17,18,19 A small 6-to-10 mm transverse incision was made on the left flank of the 
RFP nude mouse through the skin and peritoneum. The tail of the pancreas was exposed 
through this incision, and a single 1-mm3 tumor fragment was sutured to the tail of the 
pancreas using 8-0 nylon surgical sutures (Ethilon; Ethicon, Inc., NJ). On completion, the 
tail of the pancreas was returned to the abdomen and the incision was closed in one layer 
using 6-0 nylon surgical sutures (Ethilon).22-26
OBP-401 labeling of the RFP-expressing PDOX
The PDOX tumor was exposed in the peritoneal cavity during laparatomy. OBP-401 (1 × 
108 PFU/tumor) was then injected into the exposed tumor.
Imaging
PDOX tumors, labeled with genetic reporters, were imaged with a laser-scanning 
microscope (IV100; Olympus, Tokyo, Japan) 27 or a confocal laser-scanning microscope 
(FV1000; Olympus) 28 or an OV-100 Olympus Small Animal Imaging System (Olympus 
Corp.).29
Fluorescence-guided surgery
Mice were given a ketamine mixture (10 μl ketamine HCl, 7.6 μl xylazine, 2.4 μl 
acepromazine maleate, and 10 μl PBS) (i.m.) before fluorescence-guided surgery. .The 
Dino-Lite mobile imaging system was used for imaging in live mice. The portable system 
has seven filtered (wavelength) blue LEDs for excitation lighting; a 510 nm emission filter; 
a white LED switched by software, and a 1.3 megapixel sensor. This digital camera can 
magnify from ×30 up to ×200 and can readily take both pictures and videos of magnified 
green, fluorescent objects. The camera's dimensions are 10.5 × 3.2 cm and the weight is only 
105 g. This all-in-one compact digital camera makes the Dino-Lite imaging system easily 
transportable and thereby suitable for FGS.30
All animal procedures were performed under anesthesia using s.c. administration of a 
ketamine mixture (see above). OBP-401 GFP-labeled cancer cells and/or RFP stromal cells 
in the PDOX were imaged with the Dino-Lite hand-held fluorescence scope to determine the 
resection area and margin. A 20 mm incision was made at the lateral midline of the 
abdomen. The pancreatic tumor was then exposed. Either under bright light or fluorescence 
tumor was resected using a scalp and foreceps. Fluorescence imaging with the Dino-Lite 
was performed to visualize residual GFP cancer cells or RFP stroma. The resected area of 
the pancreas was closed with a 6-0 suture. After surgery, the abdominal wall was closed 
with 6-0 suture.
Statistical analysis
PASW Statistics 18.0 (SPSS, Inc) was used for all statistical analyses. Data are shown as 
mean ± SD. For comparison between two groups, significant differences were determined 
using Student's t-test. P values of < 0.05 were considered significant.
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Results and Discussion
FGS of OBP-401-GFP
Time-lapse imaging showed that pancreatic cancer cells in the PDOX model were labeled by 
OB-401 three days after OBP-401 infection. GFP fluorescence remained sufficiently strong 
to use FGS 5 days after OBP-401 infection (Fig. 1A). The margin between the tumor and 
pancreas was very unclear under bright-light (Fig. 1A). In contrast, OBP-401 made the 
tumor margin much clearer than under bright-light (Fig. 1A). Using the Dino-Lite 
fluorescence digital camera system, the margin between tumor and normal was visualized 
sufficiently clearly for FGS of the pancreatic tumor (Fig. 1B, 1C). Whole-tumor and cross-
section imaging demonstrated that OBP-401 labeled the whole tumor (Fig. 1D).
FGS detects and resects residual cancer cells in OBP-401-GFP-labeled PDOX after BLS
PDOX tumors were initially resected by BLS 5 days after injection of OBP-401 (Fig. 2A). 
After BLS, confocal laser microscopy detected residual GFP-expressing cancer (Fig. 2B) at 
the single cell level. The residual cancer cells were then resected by FGS (Fig. 2C).
BLS of PDOX labeled with RFP stroma
Pancreatic cancer PDOX, previously grown in RFP transgenic nude mice in order to acquire 
RFP stroma cells, were orthotopically transplanted to non-colored nude mice.17,18,31 The 
RFP-expressing stroma cells were readily imaged in the PDOX (Fig. 3A). Residual RFP-
expressing stromal cells were readily visualized after BLS (Fig. 3A, 3B).
OBP-401-GFP labeling of PDOX with RFP stromal cells
Pancreatic cancer PDOX with RFP-expressing stroma were labeled with GFP in their cancer 
cells by administration of OBP-401 (Fig 4A). The pancreatic cancer PDOX with RFP-
expressing stroma and GFP-labeled cancer cells was incompletely resected by BLS (Fig. 
4B). Fluorescence imaging demonstrated that there were residual GFP-expressing cancer 
cells and RFP-expressing stroma cells after BLS (Fig. 4B).
FGS completely resects pancreatic cancer PDOX with GFP-expressing cancer cells and 
RFP-expressing stroma cells
GFP and RFP imaging showed that cancer and stromal cells in the color-coded labeled 
PDOX invaded beyond the tumor capsule (Fig. 4C, 4D). However, FGS enabled complete 
resection of the PDOX with GFP-expressing cancer cells and RFP-expressing stroma cells 
(Fig. 4B, Fig. 5, Supplementary Movie 1).
Color-coded FGS enables recurrence-free surgery
Two months after BLS, eight of ten mice had local recurrences (Table 1). Five of twelve 
mice which received FGS of RFP stroma-labeled PDOX had local recurrences (Table 1). 
Four of eleven mice which received FGS of GFP-labeled PDOX had local recurrences 
(Table 1). In contrast, there was no local recurrence in nine mice which received FGS of the 
color-coded PDOX with GFP-labeled cancer cells and RFP stroma cells (Fig. 6, Table 1). 
These data demonstrated that dual-color FGS resulted in complete resection and prevented 
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local recurrence of the pancreatic cancer PDOX, which BLS or single-color FGS failed to 
do.
OBP-401 selectively labeled cancer cells in the pancreatic cancer PDOX with RFP-
expressing stroma. The double-labeled PDOX enabled precise visualization of color-coded 
cancer and stromal cells after BLS and improved the efficacy of FGS.
Tumor-specific antibodies conjugated with fluorophores can only access the tumor from the 
outside and cannot label all the cancer cells in the central part of the PDOX. The present 
study demonstrated that OBP-401 infection labels cancer cells with GFP within the tumor 
and this signal, along with the RFP-expressing stromal cells, remained sufficiently strong to 
perform FGS 5 days after infection.
Future experiments will develop reporter gene vectors to target the stromal cells in order to 
apply color-coded cancer cell-stromal cell labeling for FGS in the clinic.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. OBP-401 based FGS of a pancreatic cancer PDOX
A. Representative intravital images of a pancreatic cancer patient-derived orthotopic 
xenograft (PDOX) labeled with OBP-401-GFP three days after infection (upper and middle 
panels) and five days after infection (lower panels). B. FGS of GFP labeled PDOX was 
performed with a Dino-Lite hand-held fluorescence scope. C. Representative intravital 
images before and after FGS. D. Representative images of resected tumor image (upper) and 
cross section (lower). Images were acquired with the OV100 fluorescence microscope.
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Figure 2. OBP-401 based FGS for residual cancer cells in PDOX under BLS
A. Representative intravital images of GFP-labeled PDOX five days after infection and 
before BLS. Bright-field images (upper panels) and fluorescence images (lower panels). B. 
Representative images of residual cancer cells. Images were acquired with a confocal laser 
scanning microscope FV1000 (Olympus). Low-magnification image (left panel) and high-
magnification image (right panel). C. Representative intravital images before and after FGS 
of GFP-labeled residual tumor in PDOX after BLS. After BLS, FGS was performed using 
the Dino-Lite hand-held fluorescence scope.
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Figure 3. BLS of PDOX labeled with RFP stroma cells
A. Representative intravital images of PDOX labeled with RFP stroma cells before and after 
BLS. B. Representative images of tumor resected by BLS.
Yano et al. Page 11
Cancer Gene Ther. Author manuscript; available in PMC 2016 January 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 4. FGS of residual GFP cancer cells and RFP stroma cells in PDOX remaining after BLS
A. Representative intravital images of PDOX labeled with RFP stroma cells, acquired by a 
passage in an RFP transgenic mouse before and after OBP-401 labeling. Bright-field images 
(left panel) and fluorescence images (right panel). Images were acquired with the OV100. B. 
Representative intravital images of residual GFP cancer cells and RFP stroma cells after 
BLS and FGS after BLS were acquired with the FV1000 confocal laser microscope. Low-
magnification images (upper panels) and high-magnification images (lower panels) images 
obtained with the OV100. C. Representative images of a dual-color tumor resected by FGS. 
D. High-magnification image from 2C of resected two-color tumor. Image was acquired 
with the FV1000.
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Figure 5. FGS of PDOX with GFP-labeled cancer cells and RFP-labeled stroma
A. Representative intravital images of a PDOX with RFP stroma before labeling with 
OBP-401 (left panels); after 0BP-401-GFP labeling (middle panels); and after FGS (right 
panels). Images were acquired with the OV100 before FGS and after FGS. B. 
Representative images of resected dual-color tumor after FGS. Images were acquired with 
the OV100 fluorescence imaging system. C. Representative image of a cross section of the 
resected dual-color tumor. Image was acquired with the FV1000 confocal laser microscope.
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Figure 6. Comparison of the extent of tumor recurrence after different modalities of surgery
Tumors were resected by either BLS or FGS with tumors labeled either with RFP stroma 
only, GFP cancer cells only, or with both RFP-labeled stroma and GFP-labeled cancer cells. 
Please see Materials and Methods for details.
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TABLE 1
Comparison of local recurrence after indicated surgery methods.
Surgical method Positive Negative
BLS only 10 2
Single-color FGS of RFP stroma-labeled PDOX 5 7
Single-color FGS of GFP cancer cells-labeled PDOX 4 7
Dual-color FGS of PDOX with GFP cancer cells and RFP stroma cells 0 9
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